GAMMA Investing LLC Buys 1,004 Shares of Exelixis, Inc. (NASDAQ:EXEL)

GAMMA Investing LLC boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 50.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,010 shares of the biotechnology company’s stock after buying an additional 1,004 shares during the quarter. GAMMA Investing LLC’s holdings in Exelixis were worth $78,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Handelsbanken Fonder AB boosted its holdings in Exelixis by 28.1% in the third quarter. Handelsbanken Fonder AB now owns 78,466 shares of the biotechnology company’s stock valued at $2,036,000 after acquiring an additional 17,200 shares during the last quarter. Sanctuary Advisors LLC bought a new position in shares of Exelixis in the 2nd quarter valued at about $652,000. Creative Planning grew its position in shares of Exelixis by 0.8% during the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock worth $1,611,000 after buying an additional 548 shares during the period. Algert Global LLC raised its stake in shares of Exelixis by 7.6% during the second quarter. Algert Global LLC now owns 276,352 shares of the biotechnology company’s stock worth $6,210,000 after buying an additional 19,559 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in Exelixis by 62.1% in the second quarter. Mackenzie Financial Corp now owns 433,311 shares of the biotechnology company’s stock valued at $9,736,000 after buying an additional 166,057 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on EXEL shares. Royal Bank of Canada upped their target price on shares of Exelixis from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. JMP Securities restated a “market outperform” rating and set a $29.00 target price on shares of Exelixis in a report on Friday, October 11th. Morgan Stanley upped their price target on Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. Finally, HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research note on Wednesday, September 18th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Exelixis has a consensus rating of “Moderate Buy” and an average target price of $28.43.

Insider Activity at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total transaction of $659,500.00. Following the transaction, the executive vice president now owns 605,325 shares of the company’s stock, valued at $15,968,473.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, EVP Jeffrey Hessekiel sold 25,000 shares of the firm’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the sale, the executive vice president now directly owns 605,325 shares in the company, valued at approximately $15,968,473.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Maria C. Freire sold 8,250 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total value of $219,120.00. Following the completion of the sale, the director now owns 91,007 shares in the company, valued at $2,417,145.92. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 327,858 shares of company stock valued at $8,640,129. 2.85% of the stock is owned by insiders.

Exelixis Price Performance

EXEL stock opened at $28.50 on Wednesday. The stock has a market capitalization of $8.64 billion, a P/E ratio of 44.53, a P/E/G ratio of 0.54 and a beta of 0.54. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $28.99. The business has a 50-day moving average of $26.29 and a 200-day moving average of $23.72.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. The firm had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. Equities analysts expect that Exelixis, Inc. will post 1.59 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.